Ranbaxy Laboratories Ltd Merged Nine Monthly Results

Gross Sales

8,177.83

7,745.22

9,582.08

6,217.97

6,459.95

Excise Duty

0

0

0

0

10.97

Net Sales

8,177.83

7,745.22

9,582.08

6,217.97

6,448.97

Other Operating Income

117.52

162.44

166.42

185.36

383.04

Other Income

53.52

123.9

335.19

138.99

871.78

Total Income

8,348.87

8,031.56

10,083.7

6,542.33

7,703.81

Total Expenditure

7,380.77

8,419.5

8,218.34

5,884.02

5,283.35

PBIDT

968.1

-387.92

1,865.35

658.3

2,420.45

Interest

426.57

323.13

167.94

215.52

46.86

PBDT

541.53

-711.05

1,697.41

442.79

2,373.6

Depreciation

306.1

0

0

225.88

268.73

Minority Interest Before NP

0

0

0

0

0

Tax

967.73

123.44

259.85

122.26

496.92

Deferred Tax

0

0

0

0

0

Reported Profit After Tax

-732.3

-834.5

1,437.55

94.63

1,607.93

Minority Interest After NP

8.52

6.92

6.19

6.8

9.25

Net Profit after Minority Interest

-737.9

-852.65

1,415.2

83.04

1,594.22

Extra-ordinary Items

724.45

-641.4

117.45

-126.3

416.85

Adjusted Profit After Extra-ordinary item

-1,462.35

-211.24

1,297.74

209.34

1,177.37

EPS (Unit Curr.)

-17.4

-20.17

33.31

1.97

37.9

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

212.24

211.57

211.13

210.75

210.38

Public Shareholding (Number)

15,62,89,856

14,28,03,328

14,50,30,480

14,54,62,448

14,62,07,728

Public Shareholding (%)

36.77

33.75

34.34

34.5

34.75

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

26,87,11,328

26,37,11,328

26,87,11,328

26,87,11,328

26,87,11,328

Non Encumbered - % in Total Promoters Holding

100

100

100

100

100

Non Encumbered - % in Total Equity

63.22

63.5

63.63

63.75

63.86

PBIDTM(%)

11.83

-5

19.46

10.58

37.53

PBDTM(%)

6.62

-9.18

17.71

7.12

36.8

PATM(%)

-8.95

-10.77

15

1.52

24.93